These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31611701)

  • 1. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity.
    Wang G; Chow RD; Bai Z; Zhu L; Errami Y; Dai X; Dong MB; Ye L; Zhang X; Renauer PA; Park JJ; Shen L; Ye H; Fuchs CS; Chen S
    Nat Immunol; 2019 Nov; 20(11):1494-1505. PubMed ID: 31611701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
    Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
    Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replicating viral vector platform exploits alarmin signals for potent CD8
    Kallert SM; Darbre S; Bonilla WV; Kreutzfeldt M; Page N; Müller P; Kreuzaler M; Lu M; Favre S; Kreppel F; Löhning M; Luther SA; Zippelius A; Merkler D; Pinschewer DD
    Nat Commun; 2017 May; 8():15327. PubMed ID: 28548102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
    Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH
    Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
    Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
    Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.
    Smith KA; Meisenburg BL; Tam VL; Pagarigan RR; Wong R; Joea DK; Lantzy L; Carrillo MA; Gross TM; Malyankar UM; Chiang CS; Da Silva DM; Kündig TM; Kast WM; Qiu Z; Bot A
    Clin Cancer Res; 2009 Oct; 15(19):6167-76. PubMed ID: 19789304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.
    Rodríguez-Ruiz ME; Perez-Gracia JL; Rodríguez I; Alfaro C; Oñate C; Pérez G; Gil-Bazo I; Benito A; Inogés S; López-Diaz de Cerio A; Ponz-Sarvise M; Resano L; Berraondo P; Barbés B; Martin-Algarra S; Gúrpide A; Sanmamed MF; de Andrea C; Salazar AM; Melero I
    Ann Oncol; 2018 May; 29(5):1312-1319. PubMed ID: 29554212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Let's fight cancer: let-7 is a tool to enhance antitumor immune responses.
    Pobezinsky LA; Wells AC
    Future Oncol; 2018 May; 14(12):1141-1145. PubMed ID: 29683340
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy.
    Kanwar JR; Shen WP; Kanwar RK; Berg RW; Krissansen GW
    J Natl Cancer Inst; 2001 Oct; 93(20):1541-52. PubMed ID: 11604477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.
    Qu Y; Chen L; Lowe DB; Storkus WJ; Taylor JL
    Mol Ther; 2012 Mar; 20(3):644-51. PubMed ID: 22215017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
    Ballesteros-Briones MC; Martisova E; Casales E; Silva-Pilipich N; Buñuales M; Galindo J; Mancheño U; Gorraiz M; Lasarte JJ; Kochan G; Escors D; Sanchez-Paulete AR; Melero I; Prieto J; Hernandez-Alcoceba R; Hervas-Stubbs S; Smerdou C
    Mol Ther; 2019 Nov; 27(11):1892-1905. PubMed ID: 31563534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Locking Nanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy.
    Zhang Z; Wang Q; Liu Q; Zheng Y; Zheng C; Yi K; Zhao Y; Gu Y; Wang Y; Wang C; Zhao X; Shi L; Kang C; Liu Y
    Adv Mater; 2019 Dec; 31(51):e1905751. PubMed ID: 31709671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
    Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy.
    Zhu J; Liu JQ; Shi M; Cheng X; Ding M; Zhang JC; Davis JP; Varikuti S; Satoskar AR; Lu L; Pan X; Zheng P; Liu Y; Bai XF
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.